FULC Fulcrum Therapeutics, Inc.
$3.80▲ +0.00%
Healthcare
Other
After hours
$3.80▲ +0.00%
Sep 11, 4:10 PM ET
Volume 814.8K
Avg Volume (10D) 1.41M
Key Metrics & Fundamentals
Market Cap
$289.93M
P/E Ratio
–
Div Yield
–%
52W Range
2.83 - 15.74
% vs 50 MA
1.33%
% vs 200 MA
-47.12%
RSI-14
47.2
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.72
Free Cash Flow
-$16.15M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$10.29M
COGS
–
Operating Exp
$19.91M
Operating Income
-$19.91M
EBIT
-$19.91M
Pretax Income
-$26.18M
Net Income
-$26.18M
EPS (Diluted)
-0.34
Price & Volume History
Loading chart…
Recent News
Slate Medicines Starts Migraine Treatment Study
Exec Edge · Aug 27, 2026 9:49 PM
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
Insider Monkey · Aug 25, 2026 6:28 PM
Fulcrum and Slate Medicines sign merger agreement
Pharmaceutical Technology · Aug 18, 2026 8:56 AM
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
Exec Edge · Aug 17, 2026 4:11 PM
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
MarketBeat · Aug 17, 2026 1:02 PM
Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger
MT Newswires · Aug 17, 2026 11:52 AM
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
GlobeNewswire · Aug 17, 2026 11:00 AM
Slate, Fulcrum to combine in reverse merger
BioPharma Dive · Aug 17, 2026 10:23 AM
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
Simply Wall St. · Aug 5, 2026 8:12 AM
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
Simply Wall St. · Jun 27, 2026 8:06 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See FULC's money flow as a full page
Social Sentiment
Avg +0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.